文献速递核素与放射性配体治疗

简化个体化剂量学方案在[177Lu]Lu-DOTATATE放射配体治疗的神经内分泌肿瘤患者中与标准方案的比较:以促进临床实践应用

A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-01-23

在30例接受[177Lu]Lu-DOTATATE放射配体治疗的神经内分泌肿瘤患者中,比较标准方案(每周期后计算累积吸收剂量,M0)与两种简化方案(仅第一周期后计算,M1;第一和末周期后计算,M2)。M1与M0的累积吸收剂量平均差异为肾脏-10%、脾脏-5%、肝脏+34%、红骨髓+13%、肿瘤病灶+37%;M2与M0差异均低于±10%。结论认为M2方案所得累积吸收剂量与M0相似,而M1方案除脾脏外高估了所有危及器官的吸收剂量。

要点

  • M2方案(第一和末周期后剂量学)与标准M0方案的累积吸收剂量差异均低于±10%。
  • M1方案(仅第一周期后剂量学)除脾脏外高估所有危及器官的吸收剂量。
  • 简化剂量学方案可能有助于促进个体化剂量学在临床实践中的应用。

核心结论

  • M2方案获得的累积吸收剂量与M0方案相似,而M1方案除脾脏外高估了所有危及器官的吸收剂量。

研究设计与样本

  • 在30例接受[177Lu]Lu-DOTATATE放射配体治疗的神经内分泌肿瘤患者中进行剂量学评估。
  • 参考方法M0在每个(共四个)周期后计算累积吸收剂量。
  • 简化方案M1仅在第一个周期后定义剂量学,M2在第一个和最后一个周期后定义剂量学。

主要发现

  • M1与M0的累积吸收剂量平均差异:肾脏-10%、脾脏-5%、肝脏+34%、红骨髓+13%、肿瘤病灶+37%。
  • M2与M0的累积吸收剂量差异低于±10%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The role of internal dosimetry is usually proposed for investigational purposes in patients treated by RLT, even if its application is not yet the standard method in clinical practice. This limited use is partially justified by several concomitant factors that make calculations a complex process. Therefore, simplified dosimetry protocols are required. METHODS: In our study, dosimetric evaluations were performed in thirty patients with NENs who underwent RLT with [177Lu]Lu-DOTATATE. The reference method (M0) calculated the cumulative absorbed dose performing dosimetry after each of the four cycles. Obtained data were employed to assess the feasibility of simplified protocols: defining the dosimetry only after the first cycle (M1) and after the first and last one (M2). RESULTS: The mean differences of the cumulative absorbed doses between M1 and M0 were - 10% for kidney, - 5% for spleen, + 34% for liver, + 13% for red marrow, and + 37% for tumor lesions. Conversely, differences lower than ± 10% were measured between M2 and M0. CONCLUSION: Cumulative absorbed doses obtained with the M2 protocol resembled the doses calculated by M0, while the M1 protocol overestimated the absorbed doses in all organs at risk, except for the spleen.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Pirozzi Palmese V, D'Ambrosio L, Di Gennaro F, et al. A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice. Eur J Nucl Med Mol Imaging. 2023. PMID: 36688980. doi:10.1007/s00259-023-06112-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。